FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1924166307> ?p ?o ?g. }

• W1924166307 abstract "Ankylosing spondylitis (AS) is a chronic inflammatory arthritis characterised by severe inflammation of the axial skeleton followed by bone formation that can lead to ankylosis. The mechanisms mediating the transition from inflammation to bone formation are poorly understood due to the limited availability of relevant bone samples. Therefore, we used the proteoglycan-induced spondylitis (PGISp) mouse model to delineate the morphological changes during axial disease development. This mouse model develops spondylitis followed by ankylosis, mimicking the clinical progression seen in patients with AS. The first part of this project aimed to characterise the disease progression across a 43-week time-course in the PGISp mouse model. The principal assessment for analysing spinal disease was a semi-quantitative histological score that assessed joint inflammation, joint destruction (including intervertebral disc (IVD), cartilage and bone) and excessive tissue formation (peri-joint mesenchymal tissue expansion or fibrocartilage formation). Early inflammation initiated at the periphery of the IVD and was followed by varying levels of disc, cartilage and bone damage. In the advanced stages of disease, excessive tissue formation and ectopic chondrocyte expansion, ectopic bone and osteophyte formation were the key features. Abnormal tissue formation was always associated with IVD destruction, which was the result of inflammation, indicating that inflammation-derived IVD destruction is a prerequisite for induction of excessive tissue formation and the subsequent osteoproliferation. Current therapies for AS include non-steroidal anti-inflammatory drugs (NSAIDs), tumour necrosis factor (TNF) inhibitors and physiotherapy. However, these therapies aim to alleviate symptoms but cannot prevent syndesmophyte formation; hence new, more effective, therapeutic strategies are required. Genome-wide association studies have shown that AS is strongly associated with prostaglandin E2 (PGE2) receptor subtype 4 (EP4), which plays regulatory roles in both inflammation and bone formation. The involvement of EP4 in AS has not been examined. The second objective of this thesis was to examine the hypothesis that blocking EP4 can suppress disease progression by inhibiting both inflammation and bone formation. PGISp mice were prophylactically administered with ONO-AE1-329 (an EP4 agonist) or ONO-AE2-227 (an EP4 antagonist) for 16 weeks. Indomethacin, an NSAID, was included as a positive control of PGE2 signalling inhibitor. None of the treatments significantly altered peripheral arthritis or axial disease progression. Use of EP4 agonist or antagonist did not change bone mineral density and bone mineral content as measured by dual-energy X-ray absorptiometry. The large variation of disease onset and features within each experimental group confounded the analysis. The third objective was to test the hypothesis that inflammation-derived IVD destruction is a prerequisite for excessive tissue formation. To suppress the onset and severity of inflammation development, a combination of high dose etanercept plus high dose prednisolone was administered in the initial stage of axial disease development. This anti-inflammatory therapy was found to significantly suppress peripheral inflammation and delay disease onset. It also reduced axial inflammation and led to a trend toward reduced IVD destruction, bone erosion, cartilage damage and excessive tissue formation. Suppressing inflammation ameliorated disease progression supporting that early and aggressive anti-inflammatory intervention might mediate genuine clinical improvements with respect to structural damage. In conclusion, enthesitis and excessive cartilage/bone formation were the key features of the PGISp mouse, making it a suitable model for understanding the pathological mechanisms that are involved in the transition from inflammation to osteoproliferation. The IVD destruction driven by inflammation is a prerequisite for induction of osteoproliferation. Therefore, early intervention with anti-inflammatory therapy might prevent structural damage and further suppress excessive tissue formation." @default.
• W1924166307 created "2016-06-24" @default.
• W1924166307 creator A5090515811 @default.
• W1924166307 date "2015-10-01" @default.
• W1924166307 modified "2023-09-26" @default.
• W1924166307 title "Inflammation-driven bone formation in ankylosing spondylitis: characterisation of the proteoglycan-induced spondylitis mouse model" @default.
• W1924166307 cites W101448947 @default.
• W1924166307 cites W1484879368 @default.
• W1924166307 cites W1495122617 @default.
• W1924166307 cites W1502820929 @default.
• W1924166307 cites W1505282125 @default.
• W1924166307 cites W1524737589 @default.
• W1924166307 cites W1536883024 @default.
• W1924166307 cites W1553771325 @default.
• W1924166307 cites W1567420244 @default.
• W1924166307 cites W1567785785 @default.
• W1924166307 cites W1572866790 @default.
• W1924166307 cites W1576647157 @default.
• W1924166307 cites W1578120065 @default.
• W1924166307 cites W1621490964 @default.
• W1924166307 cites W1669999648 @default.
• W1924166307 cites W1758825137 @default.
• W1924166307 cites W1826024922 @default.
• W1924166307 cites W1878264508 @default.
• W1924166307 cites W1894940975 @default.
• W1924166307 cites W1899918226 @default.
• W1924166307 cites W1942291252 @default.
• W1924166307 cites W1951812021 @default.
• W1924166307 cites W1963483865 @default.
• W1924166307 cites W1963651279 @default.
• W1924166307 cites W1964519636 @default.
• W1924166307 cites W1964766831 @default.
• W1924166307 cites W1966756689 @default.
• W1924166307 cites W1970435428 @default.
• W1924166307 cites W1970864109 @default.
• W1924166307 cites W1971759646 @default.
• W1924166307 cites W1975137544 @default.
• W1924166307 cites W1975173830 @default.
• W1924166307 cites W1977648439 @default.
• W1924166307 cites W1978207888 @default.
• W1924166307 cites W1980624543 @default.
• W1924166307 cites W1981924088 @default.
• W1924166307 cites W1984088097 @default.
• W1924166307 cites W1984313032 @default.
• W1924166307 cites W1984588551 @default.
• W1924166307 cites W1985689832 @default.
• W1924166307 cites W1986122488 @default.
• W1924166307 cites W1987224476 @default.
• W1924166307 cites W1987640168 @default.
• W1924166307 cites W1987988486 @default.
• W1924166307 cites W1989969667 @default.
• W1924166307 cites W1991238781 @default.
• W1924166307 cites W1992611800 @default.
• W1924166307 cites W1993892793 @default.
• W1924166307 cites W1996677125 @default.
• W1924166307 cites W1999589417 @default.
• W1924166307 cites W1999882792 @default.
• W1924166307 cites W2000413455 @default.
• W1924166307 cites W2004751481 @default.
• W1924166307 cites W2006029505 @default.
• W1924166307 cites W2006704636 @default.
• W1924166307 cites W2008993230 @default.
• W1924166307 cites W2012688411 @default.
• W1924166307 cites W2013018548 @default.
• W1924166307 cites W2017037387 @default.
• W1924166307 cites W2019011319 @default.
• W1924166307 cites W2021867336 @default.
• W1924166307 cites W2026258433 @default.
• W1924166307 cites W2026495245 @default.
• W1924166307 cites W2026942180 @default.
• W1924166307 cites W2031756196 @default.
• W1924166307 cites W2032581945 @default.
• W1924166307 cites W2034516005 @default.
• W1924166307 cites W2034617410 @default.
• W1924166307 cites W2035636765 @default.
• W1924166307 cites W2035906290 @default.
• W1924166307 cites W2036364473 @default.
• W1924166307 cites W2036368043 @default.
• W1924166307 cites W2037750372 @default.
• W1924166307 cites W2038377490 @default.
• W1924166307 cites W2039229522 @default.
• W1924166307 cites W2040113209 @default.
• W1924166307 cites W2040489086 @default.
• W1924166307 cites W2041598849 @default.
• W1924166307 cites W2041745643 @default.
• W1924166307 cites W204181193 @default.
• W1924166307 cites W2042932723 @default.
• W1924166307 cites W2043827616 @default.
• W1924166307 cites W2044001309 @default.
• W1924166307 cites W2045668134 @default.
• W1924166307 cites W2045860850 @default.
• W1924166307 cites W2046579578 @default.
• W1924166307 cites W2046957298 @default.
• W1924166307 cites W2047606883 @default.
• W1924166307 cites W2048020246 @default.
• W1924166307 cites W2049477443 @default.
• W1924166307 cites W2050516476 @default.
• W1924166307 cites W2052750760 @default.
• W1924166307 cites W2053176433 @default.
• W1924166307 cites W2054215607 @default.

• next